Literature DB >> 9609746

eNOS expression is not altered in pulmonary vascular remodeling due to increased pulmonary blood flow.

A D Everett1, T D Le Cras, C Xue, R A Johns.   

Abstract

Congenital heart lesions resulting in increased pulmonary blood flow are common and if unrepaired often lead to pulmonary hypertension and heart failure. Therefore, we hypothesized that increased pulmonary blood flow without changes in pressure would result in remodeling of the pulmonary arterial wall. Furthermore, because the vasodilator nitric oxide is produced by the lung, is regulated by flow in the systemic circulation, and has been associated with the regulation of smooth muscle cell proliferation, we hypothesized that increased pulmonary blood flow would result in altered expression of endothelial nitric oxide synthase (eNOS). To study this hypothesis, 42-day-old Sprague-Dawley rats had creation of an aortocaval shunt to increase pulmonary blood flow for 6 wk. The shunt resulted in a significant increase in the heart- and lung-to-body weight ratios (>2-fold; P < 0.05) without significant alteration of pulmonary or systemic blood pressures. Significant thickening of the pulmonary arterial medial wall developed, with increased muscularization of small (50-100 micron)- and medium (101-200 micron)-sized arteries as evidenced by alpha-actin smooth muscle staining. Proliferating cell nuclear antigen staining and bromodeoxyuridine labeling did not detect proliferating smooth muscle cells in the vascular wall. eNOS Western and Northern blot analyses and immunohistochemical staining demonstrated that eNOS protein and mRNA levels were not altered in the shunt lungs compared with sham controls. Therefore, increased pulmonary flow without increased pressure resulted in pulmonary artery medial thickening, without ongoing proliferation. Unlike chronic hypoxia-induced vascular remodeling, the pulmonary vascular remodeling resulting from increased pulmonary blood flow is not associated with changes in eNOS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9609746     DOI: 10.1152/ajplung.1998.274.6.L1058

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  12 in total

1.  Transforming growth factor-β inhibition attenuates pulmonary arterial hypertension in rats.

Authors:  Aikaterini J Megalou; Chryssoula Glava; Dimitrios L Oikonomidis; Agapi Vilaeti; Maria G Agelaki; Giannis G Baltogiannis; Apostolos Papalois; Antonios P Vlahos; Theofilos M Kolettis
Journal:  Int J Clin Exp Med       Date:  2010-10-23

2.  Ruscogenin exerts beneficial effects on monocrotaline-induced pulmonary hypertension by inhibiting NF-κB expression.

Authors:  Rong Zhu; Liqing Bi; Hui Kong; Weiping Xie; Yongqing Hong; Hong Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 3.  The structural basis of pulmonary hypertension in chronic lung disease: remodelling, rarefaction or angiogenesis?

Authors:  Natalie Hopkins; Paul McLoughlin
Journal:  J Anat       Date:  2002-10       Impact factor: 2.610

4.  Changes in functional and histological distributions of nitric oxide synthase caused by chronic hypoxia in rat small pulmonary arteries.

Authors:  Mikiyasu Shirai; James T Pearson; Akito Shimouchi; Noritoshi Nagaya; Hirotsugu Tsuchimochi; Ishio Ninomiya; Hidezo Mori
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

5.  Pulmonary vascular changes in piglets with increased pulmonary blood flow and pressure.

Authors:  Matthias Gorenflo; Esther Herpel; Michael V Ullmann; Karoline Röhlig; Sueha Demirakca; Homa Klimpel; Siegfried Hagl; Martha Maria Gebhard; Philipp A Schnabel
Journal:  Virchows Arch       Date:  2007-04-21       Impact factor: 4.064

6.  Gene expressions of nitric oxide synthase and matrix metalloproteinase-2 in monocrotaline-induced pulmonary hypertension in rats after bosentan treatment.

Authors:  Hee Sun Koo; Kwan Chang Kim; Young Mi Hong
Journal:  Korean Circ J       Date:  2011-02-28       Impact factor: 3.243

Review 7.  Systemic versus localized coagulation activation contributing to organ failure in critically ill patients.

Authors:  Marcel Levi; Tom van der Poll; Marcus Schultz
Journal:  Semin Immunopathol       Date:  2011-07-30       Impact factor: 9.623

Review 8.  Breath tests in respiratory and critical care medicine: from research to practice in current perspectives.

Authors:  Attapon Cheepsattayakorn; Ruangrong Cheepsattayakorn
Journal:  Biomed Res Int       Date:  2013-09-18       Impact factor: 3.411

9.  Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury.

Authors:  Rio Dumitrascu; Silke Koebrich; Eva Dony; Norbert Weissmann; Rajkumar Savai; Soni S Pullamsetti; Hossein A Ghofrani; Arun Samidurai; Horst Traupe; Werner Seeger; Friedrich Grimminger; Ralph T Schermuly
Journal:  BMC Pulm Med       Date:  2008-12-17       Impact factor: 3.317

10.  Transforming growth factor-β inhibition and endothelin receptor blockade in rats with monocrotaline-induced pulmonary hypertension.

Authors:  Aikaterini J Megalou; Chryssoula Glava; Agapi D Vilaeti; Dimitrios L Oikonomidis; Giannis G Baltogiannis; Apostolos Papalois; Antonios P Vlahos; Theofilos M Kolettis
Journal:  Pulm Circ       Date:  2012-10       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.